Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	IgG receptor activity	FCGR2C FCGR2A FCGR2B	3.01e-07	7	42	3	GO:0019770
GeneOntologyMolecularFunction	immunoglobulin binding	FCGR2C LILRA1 FCGR2A FCGR2B	9.48e-07	36	42	4	GO:0019865
GeneOntologyMolecularFunction	IgG binding	FCGR2C FCGR2A FCGR2B	1.41e-06	11	42	3	GO:0019864
GeneOntologyMolecularFunction	immunoglobulin receptor activity	FCGR2C FCGR2A FCGR2B	3.10e-06	14	42	3	GO:0019763
GeneOntologyMolecularFunction	low-affinity IgG receptor activity	FCGR2A FCGR2B	2.58e-05	4	42	2	GO:0019772
GeneOntologyMolecularFunction	deSUMOylase activity	SENP3 SENP5	9.01e-05	7	42	2	GO:0016929
GeneOntologyMolecularFunction	ubiquitin-like protein peptidase activity	USP31 COPS6 SENP3 SENP5	1.94e-04	137	42	4	GO:0019783
GeneOntologyMolecularFunction	immune receptor activity	FCGR2C LILRA1 FCGR2A FCGR2B	3.94e-04	165	42	4	GO:0140375
GeneOntologyMolecularFunction	peptide binding	TNPO1 CMKLR2 LILRA1 FCGR2A FCGR2B	5.21e-04	318	42	5	GO:0042277
GeneOntologyMolecularFunction	amyloid-beta binding	LILRA1 FCGR2A FCGR2B	1.29e-03	102	42	3	GO:0001540
GeneOntologyMolecularFunction	deubiquitinase activity	USP31 COPS6 SENP3	2.25e-03	124	42	3	GO:0101005
GeneOntologyMolecularFunction	dynein intermediate chain binding	HTT DNAH11	2.75e-03	37	42	2	GO:0045505
GeneOntologyBiologicalProcess	antibody-dependent cellular cytotoxicity	FCGR2C FCGR2A FCGR2B	2.21e-06	13	42	3	GO:0001788
GeneOntologyBiologicalProcess	type IIa hypersensitivity	FCGR2C FCGR2A FCGR2B	3.51e-06	15	42	3	GO:0001794
GeneOntologyBiologicalProcess	type II hypersensitivity	FCGR2C FCGR2A FCGR2B	3.51e-06	15	42	3	GO:0002445
GeneOntologyBiologicalProcess	negative regulation of type I hypersensitivity	FCGR2A FCGR2B	4.05e-06	2	42	2	GO:0001811
GeneOntologyBiologicalProcess	hypersensitivity	FCGR2C FCGR2A FCGR2B	1.75e-05	25	42	3	GO:0002524
GeneOntologyBiologicalProcess	negative regulation of hypersensitivity	FCGR2A FCGR2B	2.42e-05	4	42	2	GO:0002884
GeneOntologyBiologicalProcess	regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway	FCGR2A FCGR2B	4.03e-05	5	42	2	GO:1903381
GeneOntologyBiologicalProcess	negative regulation of neutrophil apoptotic process	FCGR2A FCGR2B	4.03e-05	5	42	2	GO:0033030
GeneOntologyBiologicalProcess	neuron intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	FCGR2A FCGR2B	6.04e-05	6	42	2	GO:0036483
GeneOntologyBiologicalProcess	positive regulation of endothelial cell-matrix adhesion via fibronectin	CEACAM6 RIN2	6.04e-05	6	42	2	GO:1904906
GeneOntologyBiologicalProcess	Fc-gamma receptor signaling pathway	FCGR2C FCGR2A FCGR2B	6.82e-05	39	42	3	GO:0038094
GeneOntologyBiologicalProcess	Fc receptor-mediated immune complex endocytosis	FCGR2A FCGR2B	8.45e-05	7	42	2	GO:0160006
GeneOntologyBiologicalProcess	acute inflammatory response to antigenic stimulus	FCGR2C FCGR2A FCGR2B	8.53e-05	42	42	3	GO:0002438
GeneOntologyBiologicalProcess	regulation of endothelial cell-matrix adhesion via fibronectin	CEACAM6 RIN2	1.12e-04	8	42	2	GO:1904904
GeneOntologyBiologicalProcess	endothelial cell-matrix adhesion via fibronectin	CEACAM6 RIN2	1.12e-04	8	42	2	GO:0090674
GeneOntologyBiologicalProcess	negative regulation of acute inflammatory response to antigenic stimulus	FCGR2A FCGR2B	1.44e-04	9	42	2	GO:0002865
GeneOntologyBiologicalProcess	immune complex clearance	FCGR2A FCGR2B	1.44e-04	9	42	2	GO:0002434
GeneOntologyBiologicalProcess	regulation of type I hypersensitivity	FCGR2A FCGR2B	1.44e-04	9	42	2	GO:0001810
GeneOntologyBiologicalProcess	protein desumoylation	SENP3 SENP5	1.44e-04	9	42	2	GO:0016926
GeneOntologyBiologicalProcess	type I hypersensitivity	FCGR2A FCGR2B	1.80e-04	10	42	2	GO:0016068
GeneOntologyBiologicalProcess	endothelial cell-matrix adhesion	CEACAM6 RIN2	1.80e-04	10	42	2	GO:0090673
GeneOntologyBiologicalProcess	protein modification by small protein removal	USP31 COPS6 SENP3 SENP5	2.08e-04	144	42	4	GO:0070646
GeneOntologyBiologicalProcess	regulation of type II hypersensitivity	FCGR2A FCGR2B	2.20e-04	11	42	2	GO:0002892
GeneOntologyBiologicalProcess	regulation of type IIa hypersensitivity	FCGR2A FCGR2B	2.20e-04	11	42	2	GO:0001796
GeneOntologyBiologicalProcess	regulation of neutrophil apoptotic process	FCGR2A FCGR2B	2.20e-04	11	42	2	GO:0033029
GeneOntologyBiologicalProcess	negative regulation of humoral immune response mediated by circulating immunoglobulin	FCGR2A FCGR2B	2.64e-04	12	42	2	GO:0002924
GeneOntologyBiologicalProcess	Fc receptor signaling pathway	FCGR2C FCGR2A FCGR2B	2.73e-04	62	42	3	GO:0038093
GeneOntologyBiologicalProcess	neutrophil apoptotic process	FCGR2A FCGR2B	3.63e-04	14	42	2	GO:0001781
GeneOntologyBiologicalProcess	negative regulation of immunoglobulin mediated immune response	FCGR2A FCGR2B	4.77e-04	16	42	2	GO:0002890
GeneOntologyBiologicalProcess	negative regulation of B cell mediated immunity	FCGR2A FCGR2B	4.77e-04	16	42	2	GO:0002713
GeneOntologyBiologicalProcess	positive regulation of mitophagy	VPS13D HTT	4.77e-04	16	42	2	GO:1901526
GeneOntologyBiologicalProcess	anterograde trans-synaptic signaling	MTNR1B LILRA1 DMXL2 NLGN2 GRIN3B FCGR2A FCGR2B HTT	5.03e-04	931	42	8	GO:0098916
GeneOntologyBiologicalProcess	chemical synaptic transmission	MTNR1B LILRA1 DMXL2 NLGN2 GRIN3B FCGR2A FCGR2B HTT	5.03e-04	931	42	8	GO:0007268
GeneOntologyBiologicalProcess	trans-synaptic signaling	MTNR1B LILRA1 DMXL2 NLGN2 GRIN3B FCGR2A FCGR2B HTT	5.32e-04	939	42	8	GO:0099537
GeneOntologyBiologicalProcess	leukocyte mediated cytotoxicity	CEACAM6 FCGR2C FCGR2A FCGR2B	5.59e-04	187	42	4	GO:0001909
GeneOntologyBiologicalProcess	regulation of dendritic spine maintenance	FCGR2A FCGR2B	6.07e-04	18	42	2	GO:1902950
GeneOntologyBiologicalProcess	negative regulation of acute inflammatory response	FCGR2A FCGR2B	6.07e-04	18	42	2	GO:0002674
GeneOntologyBiologicalProcess	negative regulation of lymphocyte mediated immunity	CEACAM6 FCGR2A FCGR2B	6.44e-04	83	42	3	GO:0002707
GeneOntologyBiologicalProcess	regulation of hypersensitivity	FCGR2A FCGR2B	6.77e-04	19	42	2	GO:0002883
GeneOntologyBiologicalProcess	positive regulation of autophagy of mitochondrion	VPS13D HTT	6.77e-04	19	42	2	GO:1903599
GeneOntologyBiologicalProcess	negative regulation of humoral immune response	FCGR2A FCGR2B	6.77e-04	19	42	2	GO:0002921
GeneOntologyBiologicalProcess	synaptic signaling	MTNR1B LILRA1 DMXL2 NLGN2 GRIN3B FCGR2A FCGR2B HTT	6.87e-04	976	42	8	GO:0099536
GeneOntologyBiologicalProcess	negative regulation of immunoglobulin production	FCGR2A FCGR2B	7.51e-04	20	42	2	GO:0002638
GeneOntologyBiologicalProcess	positive regulation of macroautophagy	SESN3 VPS13D HTT	8.69e-04	92	42	3	GO:0016239
GeneOntologyBiologicalProcess	regulation of humoral immune response mediated by circulating immunoglobulin	FCGR2A FCGR2B	9.11e-04	22	42	2	GO:0002923
GeneOntologyBiologicalProcess	negative regulation of leukocyte mediated immunity	CEACAM6 FCGR2A FCGR2B	9.83e-04	96	42	3	GO:0002704
GeneOntologyBiologicalProcess	negative regulation of B cell proliferation	FCGR2A FCGR2B	9.97e-04	23	42	2	GO:0030889
GeneOntologyBiologicalProcess	positive regulation of phagocytosis	FCGR2C FCGR2A FCGR2B	1.07e-03	99	42	3	GO:0050766
GeneOntologyBiologicalProcess	positive regulation of vasculogenesis	CEACAM6 RIN2	1.09e-03	24	42	2	GO:2001214
GeneOntologyBiologicalProcess	cellular component maintenance	NLGN2 FCGR2A FCGR2B	1.14e-03	101	42	3	GO:0043954
GeneOntologyBiologicalProcess	inflammatory response to antigenic stimulus	FCGR2C FCGR2A FCGR2B	1.21e-03	103	42	3	GO:0002437
GeneOntologyBiologicalProcess	regulation of tumor necrosis factor production	FCGR2C TBC1D23 FCGR2A FCGR2B	1.21e-03	230	42	4	GO:0032680
GeneOntologyBiologicalProcess	negative regulation of interleukin-10 production	FCGR2A FCGR2B	1.28e-03	26	42	2	GO:0032693
GeneOntologyBiologicalProcess	regulation of tumor necrosis factor superfamily cytokine production	FCGR2C TBC1D23 FCGR2A FCGR2B	1.33e-03	236	42	4	GO:1903555
GeneOntologyBiologicalProcess	tumor necrosis factor production	FCGR2C TBC1D23 FCGR2A FCGR2B	1.35e-03	237	42	4	GO:0032640
GeneOntologyBiologicalProcess	regulation of acute inflammatory response to antigenic stimulus	FCGR2A FCGR2B	1.38e-03	27	42	2	GO:0002864
GeneOntologyBiologicalProcess	negative regulation of myeloid cell apoptotic process	FCGR2A FCGR2B	1.38e-03	27	42	2	GO:0033033
GeneOntologyBiologicalProcess	tumor necrosis factor superfamily cytokine production	FCGR2C TBC1D23 FCGR2A FCGR2B	1.48e-03	243	42	4	GO:0071706
GeneOntologyBiologicalProcess	B cell mediated immunity	FCGR2C LILRA1 FCGR2A FCGR2B	1.50e-03	244	42	4	GO:0019724
GeneOntologyBiologicalProcess	regulation of vasculogenesis	CEACAM6 RIN2	1.59e-03	29	42	2	GO:2001212
GeneOntologyBiologicalProcess	brain development	GDPD5 DMXL2 TBC1D23 FCGR2A FCGR2B SYNE2 HTT	1.60e-03	859	42	7	GO:0007420
GeneOntologyBiologicalProcess	dendritic spine maintenance	FCGR2A FCGR2B	1.70e-03	30	42	2	GO:0097062
GeneOntologyBiologicalProcess	antigen processing and presentation of exogenous peptide antigen via MHC class II	FCGR2A FCGR2B	1.93e-03	32	42	2	GO:0019886
GeneOntologyBiologicalProcess	negative regulation of lymphocyte proliferation	CEACAM6 FCGR2A FCGR2B	2.05e-03	124	42	3	GO:0050672
GeneOntologyBiologicalProcess	negative regulation of phagocytosis	FCGR2A FCGR2B	2.05e-03	33	42	2	GO:0050765
GeneOntologyBiologicalProcess	inflammatory cell apoptotic process	FCGR2A FCGR2B	2.05e-03	33	42	2	GO:0006925
GeneOntologyBiologicalProcess	lymphocyte mediated immunity	CEACAM6 FCGR2C LILRA1 FCGR2A FCGR2B	2.09e-03	449	42	5	GO:0002449
GeneOntologyBiologicalProcess	modulation of chemical synaptic transmission	LILRA1 NLGN2 GRIN3B FCGR2A FCGR2B HTT	2.11e-03	663	42	6	GO:0050804
GeneOntologyBiologicalProcess	regulation of trans-synaptic signaling	LILRA1 NLGN2 GRIN3B FCGR2A FCGR2B HTT	2.13e-03	664	42	6	GO:0099177
GeneOntologyBiologicalProcess	negative regulation of mononuclear cell proliferation	CEACAM6 FCGR2A FCGR2B	2.15e-03	126	42	3	GO:0032945
GeneOntologyBiologicalProcess	neutrophil homeostasis	FCGR2A FCGR2B	2.31e-03	35	42	2	GO:0001780
GeneOntologyBiologicalProcess	insulin metabolic process	CEACAM6 NLGN2	2.31e-03	35	42	2	GO:1901142
GeneOntologyBiologicalProcess	head development	GDPD5 DMXL2 TBC1D23 FCGR2A FCGR2B SYNE2 HTT	2.35e-03	919	42	7	GO:0060322
GeneOntologyBiologicalProcess	antigen processing and presentation of peptide antigen via MHC class II	FCGR2A FCGR2B	2.44e-03	36	42	2	GO:0002495
GeneOntologyBiologicalProcess	positive regulation of tumor necrosis factor production	FCGR2C FCGR2A FCGR2B	2.50e-03	133	42	3	GO:0032760
GeneOntologyBiologicalProcess	central nervous system development	GDPD5 DMXL2 ARHGEF28 TBC1D23 FCGR2A FCGR2B SYNE2 HTT	2.54e-03	1197	42	8	GO:0007417
GeneOntologyBiologicalProcess	negative regulation of leukocyte proliferation	CEACAM6 FCGR2A FCGR2B	2.56e-03	134	42	3	GO:0070664
GeneOntologyBiologicalProcess	negative regulation of inflammatory response to antigenic stimulus	FCGR2A FCGR2B	2.58e-03	37	42	2	GO:0002862
GeneOntologyBiologicalProcess	regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	FCGR2A FCGR2B	2.58e-03	37	42	2	GO:1902235
GeneOntologyBiologicalProcess	regulation of phagocytosis	FCGR2C FCGR2A FCGR2B	2.67e-03	136	42	3	GO:0050764
GeneOntologyBiologicalProcess	antigen processing and presentation of peptide or polysaccharide antigen via MHC class II	FCGR2A FCGR2B	2.72e-03	38	42	2	GO:0002504
GeneOntologyBiologicalProcess	regulation of mitophagy	VPS13D HTT	2.72e-03	38	42	2	GO:1901524
GeneOntologyBiologicalProcess	positive regulation of tumor necrosis factor superfamily cytokine production	FCGR2C FCGR2A FCGR2B	2.72e-03	137	42	3	GO:1903557
GeneOntologyBiologicalProcess	regulation of synaptic plasticity	LILRA1 FCGR2A FCGR2B HTT	2.92e-03	293	42	4	GO:0048167
GeneOntologyBiologicalProcess	regulation of long-term neuronal synaptic plasticity	FCGR2A FCGR2B	3.01e-03	40	42	2	GO:0048169
GeneOntologyBiologicalProcess	acute inflammatory response	FCGR2C FCGR2A FCGR2B	3.07e-03	143	42	3	GO:0002526
Domain	Ig_2	CEACAM6 LILRA1 FCGR2A FCGR2B	1.95e-05	73	41	4	PF13895
Domain	Peptidase_C48	SENP3 SENP5	9.81e-05	7	41	2	PF02902
Domain	ULP_PROTEASE	SENP3 SENP5	9.81e-05	7	41	2	PS50600
Domain	Peptidase_C48_C	SENP3 SENP5	9.81e-05	7	41	2	IPR003653
Domain	ig	CEACAM6 LILRA1 FCGR2A FCGR2B	7.83e-04	190	41	4	PF00047
Domain	Immunoglobulin	CEACAM6 LILRA1 FCGR2A FCGR2B	7.83e-04	190	41	4	IPR013151
Domain	-	TOGARAM2 TNPO1 EFR3B HTT	1.39e-03	222	41	4	1.25.10.10
Domain	IGc2	CEACAM6 LILRA1 FCGR2A FCGR2B	1.72e-03	235	41	4	SM00408
Domain	Ig_sub2	CEACAM6 LILRA1 FCGR2A FCGR2B	1.72e-03	235	41	4	IPR003598
Domain	ARM-like	TOGARAM2 TNPO1 EFR3B HTT	2.84e-03	270	41	4	IPR011989
Domain	HEAT	TNPO1 HTT	4.98e-03	48	41	2	PF02985
Domain	ARM-type_fold	TOGARAM2 TNPO1 EFR3B HTT	6.36e-03	339	41	4	IPR016024
Domain	HEAT	TNPO1 HTT	7.19e-03	58	41	2	IPR000357
Domain	HEAT_REPEAT	TNPO1 HTT	1.03e-02	70	41	2	PS50077
Domain	IG	CEACAM6 LILRA1 FCGR2A FCGR2B	1.34e-02	421	41	4	SM00409
Domain	Ig_sub	CEACAM6 LILRA1 FCGR2A FCGR2B	1.34e-02	421	41	4	IPR003599
Pathway	BIOCARTA_BLYMPHOCYTE_PATHWAY	FCGR2A FCGR2B	1.82e-04	10	29	2	MM1354
Pubmed	Functional Fcgamma receptor polymorphisms are associated with human allergy.	FCGR2C FCGR2A FCGR2B	1.64e-09	3	42	3	24586589
Pubmed	Nonallelic homologous recombination of the FCGR2/3 locus results in copy number variation and novel chimeric FCGR2 genes with aberrant functional expression.	FCGR2C FCGR2A FCGR2B	1.64e-09	3	42	3	26133275
Pubmed	SNPs of Fc-gamma receptor genes and chronic periodontitis.	FCGR2C FCGR2A FCGR2B	1.63e-08	5	42	3	20439936
Pubmed	Copy number, linkage disequilibrium and disease association in the FCGR locus.	FCGR2C FCGR2A FCGR2B	1.63e-08	5	42	3	20508037
Pubmed	Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B.	FCGR2C FCGR2A FCGR2B	1.63e-08	5	42	3	19309690
Pubmed	Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation.	LILRA1 FCGR2A FCGR2B	1.37e-07	9	42	3	17420263
Pubmed	CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production.	CEACAM6 FCGR2A FCGR2B	1.32e-06	18	42	3	25692415
Pubmed	Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection.	FCGR2A FCGR2B	1.42e-06	2	42	2	23616574
Pubmed	FcgammaRIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan.	FCGR2A FCGR2B	1.42e-06	2	42	2	19284648
Pubmed	FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis.	FCGR2A FCGR2B	1.42e-06	2	42	2	24842758
Pubmed	Functional Role of FcγRIIB in the Regulation of Mesenchymal Stem Cell Function.	FCGR2A FCGR2B	1.42e-06	2	42	2	26941575
Pubmed	Differential role of three major New Zealand Black-derived loci linked with Yaa-induced murine lupus nephritis.	FCGR2A FCGR2B	1.42e-06	2	42	2	15634937
Pubmed	Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity.	FCGR2A FCGR2B	1.42e-06	2	42	2	17548594
Pubmed	Follicular dendritic cell (FDC)-FcgammaRIIB engagement via immune complexes induces the activated FDC phenotype associated with secondary follicle development.	FCGR2A FCGR2B	1.42e-06	2	42	2	17013985
Pubmed	Intraperitoneal Immunization with Cry1Ac Protoxin from Bacillus thuringiensis Provokes Upregulation of Fc-Gamma-II/and Fc-Gamma-III Receptors Associated with IgG in the Intestinal Epithelium of Mice.	FCGR2A FCGR2B	1.42e-06	2	42	2	25904149
Pubmed	Development of self-reactive germinal center B cells and plasma cells in autoimmune Fc gammaRIIB-deficient mice.	FCGR2A FCGR2B	1.42e-06	2	42	2	21078890
Pubmed	FcγRIIB is a T cell checkpoint in antitumor immunity.	FCGR2A FCGR2B	1.42e-06	2	42	2	33616086
Pubmed	Etanercept prevents TNF-α mediated mandibular bone loss in FcγRIIb-/- lupus model.	FCGR2A FCGR2B	1.42e-06	2	42	2	33861790
Pubmed	Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria.	FCGR2A FCGR2B	1.42e-06	2	42	2	17435165
Pubmed	Allergen-specific IgG antibody signaling through FcγRIIb promotes food tolerance.	FCGR2A FCGR2B	1.42e-06	2	42	2	28479335
Pubmed	Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus.	FCGR2A FCGR2B	1.42e-06	2	42	2	10508186
Pubmed	Lupus-like Disease in FcγRIIB-/- Mice Induces Osteopenia.	FCGR2A FCGR2B	1.42e-06	2	42	2	31758072
Pubmed	Development of murine lupus involves the combined genetic contribution of the SLAM and FcgammaR intervals within the Nba2 autoimmune susceptibility locus.	FCGR2A FCGR2B	1.42e-06	2	42	2	20018631
Pubmed	FcgammaRIIb inhibits allergic lung inflammation in a murine model of allergic asthma.	FCGR2A FCGR2B	1.42e-06	2	42	2	20179765
Pubmed	Respiratory syncytial virus persistence in macrophages upregulates Fcgamma receptors expression.	FCGR2A FCGR2B	1.42e-06	2	42	2	24509813
Pubmed	Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells.	FCGR2A FCGR2B	1.42e-06	2	42	2	26451966
Pubmed	Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-antibody complexes.	FCGR2A FCGR2B	1.42e-06	2	42	2	17142741
Pubmed	Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.	FCGR2A FCGR2B	1.42e-06	2	42	2	25568316
Pubmed	Antigen-Specific IgG ameliorates allergic airway inflammation via Fcγ receptor IIB on dendritic cells.	FCGR2A FCGR2B	1.42e-06	2	42	2	21477339
Pubmed	Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.	FCGR2A FCGR2B	1.42e-06	2	42	2	32684632
Pubmed	A lupus-suppressor BALB/c locus restricts IgG2 autoantibodies without altering intrinsic B cell-tolerance mechanisms.	FCGR2A FCGR2B	1.42e-06	2	42	2	18322187
Pubmed	Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease.	FCGR2A FCGR2B	1.42e-06	2	42	2	17322382
Pubmed	Opposite regulation of type II and III receptors for immunoglobulin G in mouse glomerular mesangial cells and in the induction of anti-glomerular basement membrane (GBM) nephritis.	FCGR2A FCGR2B	1.42e-06	2	42	2	11983693
Pubmed	Defective Fc gamma RII gene expression in macrophages of NOD mice: genetic linkage with up-regulation of IgG1 and IgG2b in serum.	FCGR2A FCGR2B	1.42e-06	2	42	2	8906852
Pubmed	Acute Kidney Injury Induced Lupus Exacerbation Through the Enhanced Neutrophil Extracellular Traps (and Apoptosis) in Fcgr2b Deficient Lupus Mice With Renal Ischemia Reperfusion Injury.	FCGR2A FCGR2B	1.42e-06	2	42	2	34248948
Pubmed	Assignment of the gene coding for human FcRII (CD32) to bands q23q24 on chromosome 1.	FCGR2A FCGR2B	1.42e-06	2	42	2	2971615
Pubmed	Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.	FCGR2A FCGR2B	1.42e-06	2	42	2	21742972
Pubmed	Negative regulation of c-kit-mediated cell proliferation by Fc gamma RIIB.	FCGR2A FCGR2B	1.42e-06	2	42	2	10201978
Pubmed	A new mouse cell-surface antigen (Ly-m20) controlled by a gene linked to Mls locus and defined by monoclonal antibodies.	FCGR2A FCGR2B	1.42e-06	2	42	2	6173319
Pubmed	Antigen-induced oligomerization of the B cell receptor is an early target of Fc gamma RIIB inhibition.	FCGR2A FCGR2B	1.42e-06	2	42	2	20083655
Pubmed	Human IgG Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and IgG-transporting placental epithelium.	FCGR2C FCGR2B	1.42e-06	2	42	2	2531080
Pubmed	CD16/32-specific biotinylated 2.4G2 single-chain Fv complexed with avidin-FITC enhances FITC-specific humoral immune response in vivo in a CD16-dependent manner.	FCGR2A FCGR2B	1.42e-06	2	42	2	19951957
Pubmed	B-lymphocyte Fc receptor-associated non-H-2 antigens are determined by a single polymorphic locus which is linked to the Mls locus.	FCGR2A FCGR2B	1.42e-06	2	42	2	303687
Pubmed	FcγRIIB mediates the inhibitory effect of aggregated α-synuclein on microglial phagocytosis.	FCGR2A FCGR2B	1.42e-06	2	42	2	26342897
Pubmed	Genomic organization of mouse Fc gamma receptor genes.	FCGR2A FCGR2B	1.42e-06	2	42	2	2138787
Pubmed	Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis.	FCGR2A FCGR2B	1.42e-06	2	42	2	12937154
Pubmed	Identification, molecular cloning, biologic properties, and tissue distribution of a novel isoform of murine low-affinity IgG receptor homologous to human Fc gamma RIIB1.	FCGR2A FCGR2B	1.42e-06	2	42	2	8683114
Pubmed	Fc receptors: rubor redux.	FCGR2A FCGR2B	1.42e-06	2	42	2	8069908
Pubmed	Genetic control of T-cell proliferative response in mice linked to chromosomes 11 and 15.	FCGR2A FCGR2B	1.42e-06	2	42	2	8824160
Pubmed	A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling.	FCGR2A FCGR2B	1.42e-06	2	42	2	8107887
Pubmed	FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis.	FCGR2A FCGR2B	1.42e-06	2	42	2	14981111
Pubmed	Regulation of allograft survival by inhibitory FcγRIIb signaling.	FCGR2A FCGR2B	1.42e-06	2	42	2	23150718
Pubmed	Expression of Fc gamma RIII defines distinct subpopulations of fetal liver B cell and myeloid precursors.	FCGR2A FCGR2B	1.42e-06	2	42	2	7664793
Pubmed	A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice.	FCGR2A FCGR2B	1.42e-06	2	42	2	22290146
Pubmed	Identification, in mouse macrophages and in serum, of a soluble receptor for the Fc portion of IgG (Fc gamma R) encoded by an alternatively spliced transcript of the Fc gamma RII gene.	FCGR2A FCGR2B	1.42e-06	2	42	2	8398981
Pubmed	Neutrophil responsiveness to IgG, as determined by fixed ratios of mRNA levels for activating and inhibitory FcgammaRII (CD32), is stable over time and unaffected by cytokines.	FCGR2A FCGR2B	1.42e-06	2	42	2	16551965
Pubmed	Analysis of a wild mouse promoter variant reveals a novel role for FcγRIIb in the control of the germinal center and autoimmunity.	FCGR2A FCGR2B	1.42e-06	2	42	2	23109709
Pubmed	FcγRIIIA Negatively Impacts Humoral Immune Responses but Not Overall Lung Inflammation in an Ovalbumin-Induced Allergic Asthma Mouse Model.	FCGR2A FCGR2B	1.42e-06	2	42	2	29597194
Pubmed	The mouse Ly-17 locus identifies a polymorphism of the Fc receptor.	FCGR2A FCGR2B	1.42e-06	2	42	2	2414215
Pubmed	Antibody modulation of antigen presentation: positive and negative effects on presentation of the tetanus toxin antigen via the murine B cell isoform of FcgammaRII.	FCGR2A FCGR2B	1.42e-06	2	42	2	11828370
Pubmed	FcγRIIB modulates splenic germinal center response against immune subversion during acute influenza A virus infection.	FCGR2A FCGR2B	1.42e-06	2	42	2	38087748
Pubmed	TLR4 links podocytes with the innate immune system to mediate glomerular injury.	FCGR2A FCGR2B	1.42e-06	2	42	2	18256364
Pubmed	The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells.	FCGR2A FCGR2B	1.42e-06	2	42	2	15592473
Pubmed	Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus.	FCGR2A FCGR2B	1.42e-06	2	42	2	21357255
Pubmed	Selective regulation of autoreactive B cells by FcgammaRIIB.	FCGR2A FCGR2B	1.42e-06	2	42	2	19327966
Pubmed	Synaptic localization of the SUMOylation-regulating protease SENP5 in the adult mouse brain.	SENP3 SENP5	1.42e-06	2	42	2	29277914
Pubmed	Augmentation of pulmonary host defense against Pseudomonas by FcgammaRIIA cDNA transfer to the respiratory epithelium.	FCGR2A FCGR2B	1.42e-06	2	42	2	10449433
Pubmed	Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses.	FCGR2A FCGR2B	1.42e-06	2	42	2	12370366
Pubmed	Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis.	FCGR2A FCGR2B	1.42e-06	2	42	2	10981970
Pubmed	Association of FcγRIIB and FcγRIIA R131H gene polymorphisms with renal involvement in Egyptian systemic lupus erythematosus patients.	FCGR2A FCGR2B	1.42e-06	2	42	2	24366619
Pubmed	Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro.	FCGR2A FCGR2B	1.42e-06	2	42	2	26245154
Pubmed	Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo.	FCGR2A FCGR2B	1.42e-06	2	42	2	24505033
Pubmed	FcgammaRIIa and FcgammaRIIIb polymorphisms were not associated with meningococcal disease in Western Norway.	FCGR2A FCGR2B	1.42e-06	2	42	2	12729187
Pubmed	The SUMO-specific protease SENP5 is required for cell division.	SENP3 SENP5	1.42e-06	2	42	2	16738315
Pubmed	The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN.	FCGR2A FCGR2B	1.42e-06	2	42	2	23411782
Pubmed	Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors.	FCGR2A FCGR2B	1.42e-06	2	42	2	2946078
Pubmed	Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgG receptor Fc gamma RIIB.	FCGR2A FCGR2B	1.42e-06	2	42	2	16476768
Pubmed	The impact of genetic susceptibility to systemic lupus erythematosus on placental malaria in mice.	FCGR2A FCGR2B	1.42e-06	2	42	2	23675429
Pubmed	Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.	FCGR2A FCGR2B	1.42e-06	2	42	2	29576376
Pubmed	Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes.	FCGR2A FCGR2B	1.42e-06	2	42	2	2529342
Pubmed	IgG receptor FcγRIIB plays a key role in obesity-induced hypertension.	FCGR2A FCGR2B	1.42e-06	2	42	2	25368023
Pubmed	Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG.	FCGR2A FCGR2B	1.42e-06	2	42	2	10330436
Pubmed	Contribution of the intracellular domain of murine Fc-gamma receptor type IIB1 to its tumor-enhancing potential.	FCGR2A FCGR2B	1.42e-06	2	42	2	8900432
Pubmed	Elk1 enhances inflammatory cell infiltration and exacerbates acute lung injury/acute respiratory distress syndrome by suppressing Fcgr2b transcription.	FCGR2A FCGR2B	1.42e-06	2	42	2	38649840
Pubmed	Polymorphism of Fc receptor on murine B cells is Igh-linked.	FCGR2A FCGR2B	1.42e-06	2	42	2	3159826
Pubmed	Intravenous immunoglobulin (IVIG) promotes brain repair and improves cognitive outcomes after traumatic brain injury in a FcγRIIB receptor-dependent manner.	FCGR2A FCGR2B	1.42e-06	2	42	2	36581304
Pubmed	Differences in endocytosis mediated by FcγRIIA and FcγRIIB2.	FCGR2A FCGR2B	1.42e-06	2	42	2	21945020
Pubmed	Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response.	FCGR2A FCGR2B	1.42e-06	2	42	2	18798552
Pubmed	Structure of the mouse beta Fc gamma receptor II gene.	FCGR2A FCGR2B	1.42e-06	2	42	2	1824594
Pubmed	Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody.	FCGR2A FCGR2B	1.42e-06	2	42	2	16925577
Pubmed	FcgRIII Deficiency and FcgRIIb Defeciency Promote Renal Injury in Diabetic Mice.	FCGR2A FCGR2B	1.42e-06	2	42	2	31534958
Pubmed	FcγRIIb on liver sinusoidal endothelium clears small immune complexes.	FCGR2A FCGR2B	1.42e-06	2	42	2	23053513
Pubmed	Leaky-gut enhanced lupus progression in the Fc gamma receptor-IIb deficient and pristane-induced mouse models of lupus.	FCGR2A FCGR2B	1.42e-06	2	42	2	31964918
Pubmed	Drp1 SUMO/deSUMOylation by Senp5 isoforms influences ER tubulation and mitochondrial dynamics to regulate brain development.	SENP3 SENP5	1.42e-06	2	42	2	34988397
Pubmed	Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells.	FCGR2A FCGR2B	1.42e-06	2	42	2	16785568
Pubmed	The pre-B cell receptor signaling for apoptosis is negatively regulated by Fc gamma RIIB.	FCGR2A FCGR2B	1.42e-06	2	42	2	11777955
Pubmed	Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis.	FCGR2A FCGR2B	1.42e-06	2	42	2	18207575
Pubmed	Failed up-regulation of the inhibitory IgG Fc receptor Fc gamma RIIB on germinal center B cells in autoimmune-prone mice is not associated with deletion polymorphisms in the promoter region of the Fc gamma RIIB gene.	FCGR2A FCGR2B	1.42e-06	2	42	2	16034080
Pubmed	A complementary DNA clone for a macrophage-lymphocyte Fc receptor.	FCGR2A FCGR2B	1.42e-06	2	42	2	3024012
Pubmed	FcgammaRIIB regulates autoreactive primary antibody-forming cell, but not germinal center B cell, activity.	FCGR2A FCGR2B	1.42e-06	2	42	2	17202351
Interaction	FCGR2C interactions	FCGR2C FCGR2A	1.21e-05	3	41	2	int:FCGR2C
Cytoband	1q23	FCGR2A FCGR2B	2.04e-04	23	42	2	1q23
Cytoband	Ensembl 112 genes in cytogenetic band chr4p16	MAN2B2 LETM1 HTT	1.11e-03	222	42	3	chr4p16
Cytoband	Ensembl 112 genes in cytogenetic band chr1q23	FCGR2C FCGR2A FCGR2B	1.17e-03	226	42	3	chr1q23
Cytoband	5q13.2	TNPO1 ARHGEF28	1.18e-03	55	42	2	5q13.2
Cytoband	4p16.3	LETM1 HTT	2.78e-03	85	42	2	4p16.3
Cytoband	Ensembl 112 genes in cytogenetic band chr2p23	TOGARAM2 EFR3B	8.27e-03	149	42	2	chr2p23
Cytoband	Ensembl 112 genes in cytogenetic band chr5q13	TNPO1 ARHGEF28	8.60e-03	152	42	2	chr5q13
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	CEACAM6 FCGR2C LILRA1 CDCP1 FCGR2A FCGR2B	2.59e-05	394	28	6	471
GeneFamily	SUMO specific peptidases	SENP3 SENP5	4.83e-05	7	28	2	984
GeneFamily	Immunoglobulin like domain containing	CEACAM6 FCGR2A FCGR2B	3.22e-03	193	28	3	594
Coexpression	TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_DN	FCGR2A FCGR2B ATP10D	1.51e-05	30	42	3	M3210
Coexpression	GSE34156_TLR1_TLR2_LIGAND_VS_NOD2_AND_TLR1_TLR2_LIGAND_24H_TREATED_MONOCYTE_UP	HCAR3 FCGR2C DMXL2 FCGR2A RIN2	1.55e-05	197	42	5	M8676
Coexpression	GSE34156_NOD2_LIGAND_VS_TLR1_TLR2_LIGAND_6H_TREATED_MONOCYTE_DN	HCAR3 FCGR2C DMXL2 FCGR2A RIN2	1.55e-05	197	42	5	M8686
Coexpression	MARTINELLI_IMMATURE_NEUTROPHIL_DN	HCAR3 FCGR2A	1.93e-04	13	42	2	M5149
Coexpression	VERHAAK_AML_WITH_NPM1_MUTATED_UP	HCAR3 LILRA1 DMXL2 FCGR2A	2.27e-04	187	42	4	M4861
Coexpression	RPS14_DN.V1_UP	CEACAM6 DMXL2 CDCP1 RIN2	2.46e-04	191	42	4	M2816
Coexpression	GSE36888_UNTREATED_VS_IL2_TREATED_STAT5_AB_KNOCKIN_TCELL_6H_UP	FCGR2C LILRA1 FCGR2A FCGR2B	2.66e-04	195	42	4	M8737
Coexpression	GSE36888_UNTREATED_VS_IL2_TREATED_TCELL_6H_UP	FCGR2C LILRA1 FCGR2A FCGR2B	2.66e-04	195	42	4	M8739
Coexpression	GSE10325_LUPUS_CD4_TCELL_VS_LUPUS_BCELL_DN	FCGR2C FCGR2A FCGR2B ATP10D	2.72e-04	196	42	4	M3085
Coexpression	GSE34156_UNTREATED_VS_6H_TLR1_TLR2_LIGAND_TREATED_MONOCYTE_UP	HCAR3 FCGR2C DMXL2 FCGR2A	2.77e-04	197	42	4	M8672
Coexpression	GSE45881_CXCR6HI_VS_CXCR1LO_COLONIC_LAMINA_PROPRIA_DN	CEACAM6 FCGR2C COPS6 FCGR2B	2.88e-04	199	42	4	M9890
Coexpression	GSE29618_MONOCYTE_VS_PDC_UP	HCAR3 FCGR2C LILRA1 RIN2	2.88e-04	199	42	4	M4945
Coexpression	GSE11924_TH1_VS_TH17_CD4_TCELL_DN	TBC1D23 CDCP1 TMEM26 ATP10D	2.88e-04	199	42	4	M3163
Coexpression	GSE19888_ADENOSINE_A3R_ACT_VS_A3R_ACT_WITH_A3R_INH_PRETREATMENT_IN_MAST_CELL_DN	USP31 PRMT9 NLGN2 SENP3	2.88e-04	199	42	4	M7332
Coexpression	GSE3691_CONVENTIONAL_VS_PLASMACYTOID_DC_SPLEEN_UP	SESN3 DMXL2 RIN2 ATP10D	2.93e-04	200	42	4	M6369
Coexpression	GSE30083_SP2_VS_SP4_THYMOCYTE_DN	FCGR2A RIN2 ATP10D SYNE2	2.93e-04	200	42	4	M5035
Coexpression	GSE29618_MONOCYTE_VS_MDC_UP	HCAR3 DMXL2 FCGR2A RIN2	2.93e-04	200	42	4	M4948
Coexpression	GSE29618_MONOCYTE_VS_MDC_DAY7_FLU_VACCINE_UP	HCAR3 DMXL2 FCGR2A RIN2	2.93e-04	200	42	4	M4966
Coexpression	GSE22886_NAIVE_CD4_TCELL_VS_MONOCYTE_DN	DMXL2 FCGR2A RIN2 ATP10D	2.93e-04	200	42	4	M4506
Coexpression	GSE10325_LUPUS_BCELL_VS_LUPUS_MYELOID_DN	LILRA1 DMXL2 FCGR2A RIN2	2.93e-04	200	42	4	M3091
Coexpression	GSE2405_0H_VS_3H_A_PHAGOCYTOPHILUM_STIM_NEUTROPHIL_UP	GDPD5 CDCP1 TMEM26 FCGR2A	2.93e-04	200	42	4	M6212
Coexpression	GSE360_L_MAJOR_VS_B_MALAYI_HIGH_DOSE_DC_UP	EFR3B HCAR3 DMXL2 SENP3	2.93e-04	200	42	4	M5209
Coexpression	HOWARD_PBMC_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_19_39YO_AS03_ADJUVANT_VS_BUFFER_1DY_UP	FCGR2C LILRA1 DMXL2 CDCP1 FCGR2A	3.29e-04	377	42	5	M40997
ToppCell	VE-granulo1-\|VE / Condition, Cell_class and T cell subcluster	LILRA1 DMXL2 FCGR2A FCGR2B RIN2	1.11e-06	196	42	5	ab3f2ce294c7e503d86254a195be0cf500a2c5e4
ToppCell	VE-granulo1\|VE / Condition, Cell_class and T cell subcluster	LILRA1 DMXL2 FCGR2A FCGR2B RIN2	1.11e-06	196	42	5	6dbd3acb30173d7f0b7bca0a82f435f00ca85835
ToppCell	Caecum-(6)_Macrophage-(61)_LYVE1_Macrophage\|Caecum / shred on region, Cell_type, and subtype	HCAR3 LILRA1 DMXL2 FCGR2A RIN2	1.17e-06	198	42	5	e684c3934c163aef4d284b69435832d2c9614f2a
ToppCell	Caecum-Macrophage-LYVE1_Macrophage\|Caecum / Region, Cell class and subclass	HCAR3 LILRA1 DMXL2 FCGR2A RIN2	1.17e-06	198	42	5	a92c0cacb775aca6bbb302bd9e22c081a112a44d
ToppCell	VE-granulo2\|VE / Condition, Cell_class and T cell subcluster	LILRA1 DMXL2 FCGR2A FCGR2B RIN2	1.20e-06	199	42	5	05b47fdc01eccee0eaf4c781eeff93c47fe0533e
ToppCell	VE-granulo2-\|VE / Condition, Cell_class and T cell subcluster	LILRA1 DMXL2 FCGR2A FCGR2B RIN2	1.20e-06	199	42	5	455e92047201ddd0c29a437a838e5fa135de7995
ToppCell	Parenchymal-10x3prime_v2-Immune_Myeloid-Macrophage_other-Macrophage_intermediate\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	HCAR3 LILRA1 DMXL2 FCGR2A FCGR2B	1.20e-06	199	42	5	ccd473accf2205c120c0d32031619e421558a861
ToppCell	Sigmoid-Macrophage-LYVE1_Macrophage\|Sigmoid / Region, Cell class and subclass	DMXL2 CDCP1 FCGR2A FCGR2B RIN2	1.23e-06	200	42	5	851a1b372ddbec522829069e69ed36a1f4832131
ToppCell	Caecum-(4)_Monocyte-(40)_Monocyte\|Caecum / shred on region, Cell_type, and subtype	HCAR3 LILRA1 DMXL2 FCGR2A RIN2	1.23e-06	200	42	5	b078058efc51f0ff4d92123b712933b32824c655
ToppCell	mLN-Macrophage\|mLN / Region, Cell class and subclass	LILRA1 DMXL2 CDCP1 FCGR2A RIN2	1.23e-06	200	42	5	68d709afd226241e002dae6d6820bccd1cfd87a1
ToppCell	Sigmoid-(6)_Macrophage-(61)_LYVE1_Macrophage\|Sigmoid / shred on region, Cell_type, and subtype	DMXL2 CDCP1 FCGR2A FCGR2B RIN2	1.23e-06	200	42	5	bc0280d52e4edc2c5edf4ead164a1c7cf3fccd60
ToppCell	Caecum-(4)_Monocyte\|Caecum / shred on region, Cell_type, and subtype	HCAR3 LILRA1 DMXL2 FCGR2A RIN2	1.23e-06	200	42	5	6bfd6ab395e09087aeedc9a7c9ada1b4b8a26194
ToppCell	Caecum-Monocyte-Monocyte\|Caecum / Region, Cell class and subclass	HCAR3 LILRA1 DMXL2 FCGR2A RIN2	1.23e-06	200	42	5	d33619b6c721eae3ebe50fba6b9d31fa99f2248f
ToppCell	mLN-(6)_Macrophage-(61)_LYVE1_Macrophage\|mLN / shred on region, Cell_type, and subtype	LILRA1 DMXL2 CDCP1 FCGR2A RIN2	1.23e-06	200	42	5	a20f5ec61d492d8a2adf695ec304b5d57296aa8f
ToppCell	Caecum-Monocyte\|Caecum / Region, Cell class and subclass	HCAR3 LILRA1 DMXL2 FCGR2A RIN2	1.23e-06	200	42	5	9e8d38d024a315512521b349e8ac7caa56219daf
ToppCell	mLN-Macrophage-LYVE1_Macrophage\|mLN / Region, Cell class and subclass	LILRA1 DMXL2 CDCP1 FCGR2A RIN2	1.23e-06	200	42	5	89cf739a3c2f5d30e547404f2f2ec6500cd1d65d
ToppCell	mLN-(6)_Macrophage\|mLN / shred on region, Cell_type, and subtype	LILRA1 DMXL2 CDCP1 FCGR2A RIN2	1.23e-06	200	42	5	6dcba82a7d322102bae205543086e84c7655b3e0
ToppCell	390C-Myeloid-Macrophage-SPP1+_Macrophage_4\|390C / Donor, Lineage, Cell class and subclass (all cells)	HCAR3 CDCP1 FCGR2A RIN2	1.97e-05	170	42	4	439167e44a1bd5ac8e1e457351dd202ec968db46
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Myeloid-Macrophage-macrophage,_alveolar-Macro_c3-EREG\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	LILRA1 DMXL2 FCGR2A ATP10D	1.97e-05	170	42	4	9ac1ef57f14418a5dd2aa16861c3df698c28f5ed
ToppCell	10x5'-GI_small-bowel-Myeloid_Monocytic\|GI_small-bowel / Manually curated celltypes from each tissue	LILRA1 DMXL2 FCGR2A RIN2	2.01e-05	171	42	4	098a7fd387357c0d4e1a6169af4d24ef95b30018
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Granulocytic-Neutrophil\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CEACAM6 HCAR3 LILRA1 FCGR2A	2.11e-05	173	42	4	dfa56753319c92ae5b337793c4d6d5f70afce546
ToppCell	10x5'-GI_small-bowel-Myeloid_Monocytic-Classical_monocytes\|GI_small-bowel / Manually curated celltypes from each tissue	LILRA1 DMXL2 FCGR2A RIN2	2.16e-05	174	42	4	05d54a36772f096047521e16a89cc42ae48d2a1d
ToppCell	10x5'-bone_marrow-Mast-Mast_cell_lympho\|bone_marrow / Manually curated celltypes from each tissue	GDPD5 HCAR3 NLGN2 ATP10D	2.52e-05	181	42	4	56fa77ae31f3b7de6e441a439c33a11353b6573a
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Macrophage-macrophage,_alveolar-Macro_c5-WDR74\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	LILRA1 CDCP1 FCGR2A FCGR2B	2.74e-05	185	42	4	68edb1bb03ed221d49e583123ca4de14252d7bc5
ToppCell	Adult-Immune-interstitial_macrophage_(C1Q_positive)-D175\|Adult / Lineage, Cell type, age group and donor	DMXL2 CDCP1 TMEM26 FCGR2A	2.74e-05	185	42	4	ab5704b96f1d368911308797d10c7c52766ab134
ToppCell	3'_v3-GI_small-bowel-Myeloid_Monocytic-Nonclassical_monocytes\|GI_small-bowel / Manually curated celltypes from each tissue	HCAR3 LILRA1 FCGR2A RIN2	2.86e-05	187	42	4	c20689022569640ebc4a878e3fe146b86fe9b386
ToppCell	10x5'-GI_large-bowel-Myeloid_Monocytic\|GI_large-bowel / Manually curated celltypes from each tissue	LILRA1 DMXL2 FCGR2A RIN2	2.92e-05	188	42	4	d0045fdda757d191dabc7853f6a6e99c0e97d93d
ToppCell	10x5'-GI_large-bowel-Myeloid_Monocytic-Classical_monocytes\|GI_large-bowel / Manually curated celltypes from each tissue	LILRA1 DMXL2 FCGR2A RIN2	2.92e-05	188	42	4	0bcf04aa47738f43c1a87dae5dc487738ee86f8c
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Classical_Monocyte-Mono_c2-CD14-HLA-DPB1\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	LILRA1 DMXL2 FCGR2A FCGR2B	3.04e-05	190	42	4	4b9bac17eb7ceadada932f2d4a20a5f176088d53
ToppCell	3'-GW_trimst-1-LargeIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CMKLR2 GDPD5 FCGR2C FCGR2B	3.04e-05	190	42	4	92fdfed12061ee9f6c7171cf8a7f3344921f2d40
ToppCell	Monocytes-Inflammatory_CD16+_macrophages\|World / Immune cells in Kidney/Urine in Lupus Nephritis	HCAR3 LILRA1 DMXL2 RIN2	3.17e-05	192	42	4	4be5c2c946337cd3e710137726358adca563f146
ToppCell	Children_(3_yrs)-Immune-monocyte-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	LILRA1 DMXL2 FCGR2A FCGR2B	3.23e-05	193	42	4	58e1930a1d80ad3729ab9604ac8ebf7308232a3d
ToppCell	Monocytes-C1QA+_Monocytes\|World / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	DMXL2 CDCP1 FCGR2A FCGR2B	3.30e-05	194	42	4	3e104e85574894c04791252d466d438fc809dde3
ToppCell	(2)_Mono_macro\|World / Oesophagus cell shreds on cell class (v1) and cell subclass (v1)	LILRA1 FCGR2A FCGR2B RIN2	3.30e-05	194	42	4	7c05525614ee8cdfcbf22cce9146a8e73af7d14e
ToppCell	mild_COVID-19_(asymptomatic)-Neutrophil\|World / disease group, cell group and cell class (v2)	HCAR3 FCGR2A HECTD3	3.32e-05	66	42	3	e71738a3a84be93053d1ed20d030e4c606f8f402
ToppCell	10x_3'_v3-lymph_node_(10x_3'_v3)-myeloid-myeloid_monocytic-intermediate_monocyte\|lymph_node_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	LILRA1 DMXL2 FCGR2A RIN2	3.37e-05	195	42	4	403d874198a7bde626b0d0b4efad8dbb34060761
ToppCell	proximal-3-Hematologic-IGSF21+_Dendritic\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	FCGR2C URB2 FCGR2A FCGR2B	3.37e-05	195	42	4	8592d0332bc82a91e173680cfd1afc5ee189b289
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Classical_Monocyte-Mono_c1-CD14-CCL3\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	LILRA1 DMXL2 FCGR2A FCGR2B	3.37e-05	195	42	4	9168267a799bbd4111b1227754ab8173ac1a4714
ToppCell	proximal-Hematologic-IGSF21+_Dendritic\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	FCGR2C URB2 FCGR2A FCGR2B	3.37e-05	195	42	4	c48ff83c48342875f06c6c9e7d5bc6084a992848
ToppCell	wk_20-22-Hematologic-Myeloid-S100A12-lo_cla._mono.\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	HCAR3 FCGR2C LILRA1 DMXL2	3.37e-05	195	42	4	66273af9882f829b6fc0e20f03f3412294d37c26
ToppCell	proximal-Hematologic-IGSF21+_Dendritic-3\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	FCGR2C URB2 FCGR2A FCGR2B	3.37e-05	195	42	4	ae9d61011e95f7840cbb154738c79745fd29943e
ToppCell	10x_3'_v3-lymph_node_(10x_3'_v3)-myeloid-myeloid_monocytic\|lymph_node_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	LILRA1 DMXL2 FCGR2A RIN2	3.43e-05	196	42	4	f943519bff51c3094776fd45889dadf9062c8379
ToppCell	distal-Hematologic-EREG+_Dendritic-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	PRMT9 LILRA1 FCGR2A FCGR2B	3.43e-05	196	42	4	c17bb7b3992bfec194bfa310f201a5c64b35868e
ToppCell	distal-Hematologic-OLR1+_Classical_Monocyte-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	LILRA1 DMXL2 FCGR2A RIN2	3.43e-05	196	42	4	80fc5b9e04ead0b38304dccbe39f66575e2bf203
ToppCell	Monocytes\|World / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	DMXL2 CDCP1 FCGR2A FCGR2B	3.43e-05	196	42	4	ab0a8f5f388c9794d7f41f99fb0a5f2fd6fff6b3
ToppCell	distal-Hematologic-EREG+_Dendritic\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	PRMT9 LILRA1 FCGR2A FCGR2B	3.43e-05	196	42	4	14c6870d125fc2bdacf4199883399cec0dd3f569
ToppCell	Monocytes-IL1B+_Monocytes\|World / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	HCAR3 DMXL2 FCGR2A FCGR2B	3.43e-05	196	42	4	7bc0735d324ac5a1661434cda4116ddd58296730
ToppCell	remission-Non-classical_Monocyte\|remission / disease stage, cell group and cell class	HCAR3 LILRA1 FCGR2A RIN2	3.43e-05	196	42	4	049d995986c20ce066bd64fcc2d2f1c2f8899883
ToppCell	distal-Hematologic-OLR1+_Classical_Monocyte\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	LILRA1 DMXL2 FCGR2A RIN2	3.43e-05	196	42	4	3f57216dbc9ef28fca09bbb8805f7c15b03b99e8
ToppCell	Bronchial_Brush-Immune-Dendritic_cells\|Bronchial_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X	PRMT9 LILRA1 FCGR2A FCGR2B	3.50e-05	197	42	4	b4d42456a8cc96d87ad8ec0e550960f3b0a3752f
ToppCell	390C-Myeloid-Monocyte-CD16+_Monocyte\|390C / Donor, Lineage, Cell class and subclass (all cells)	HCAR3 LILRA1 DMXL2 FCGR2A	3.50e-05	197	42	4	01f5f5c34e904cc0146e978cc05ed1cd86a41533
ToppCell	saliva-Mild-Moderate_progression_d12-25-Myeloid-Macrophage\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	LILRA1 DMXL2 RIN2 NUS1	3.50e-05	197	42	4	a22c0f2ffac34635c9c8221aee778e2fc78d672b
ToppCell	10x_5'_v1-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FCGR2C CDCP1 FCGR2B DNAH11	3.50e-05	197	42	4	24bcd56df43796af2833c7ce37719c76dd299c19
ToppCell	10x5'-Liver-Myeloid_Monocytic-Nonclassical_monocytes\|Liver / Manually curated celltypes from each tissue	HCAR3 LILRA1 DMXL2 FCGR2A	3.50e-05	197	42	4	b0b4a704e1137f48e2258df17285ed89684ae98d
ToppCell	PBMC-Severe-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR3 DMXL2 FCGR2A RIN2	3.50e-05	197	42	4	383d598ce3f8f5fc98bef3300e4cf7b6992aec9c
ToppCell	10x_5'_v1-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-Z\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	FCGR2C CDCP1 FCGR2B DNAH11	3.50e-05	197	42	4	ea7dd7f90be34d8e5936c9c8d35e0918ae64433b
ToppCell	(6)_Macrophage\|World / shred on Cell_type and subtype	LILRA1 DMXL2 FCGR2A RIN2	3.50e-05	197	42	4	010b275d4da4a896175ad7fbaa96d1dc11a0b744
ToppCell	medial-Hematologic-Interstitial_Macrophage-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	LILRA1 DMXL2 FCGR2A FCGR2B	3.50e-05	197	42	4	b90c8a41e99c87b46be699d03cd49c97a2ad51af
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TOGARAM2 GRIN3B SYNE2 DNAH11	3.50e-05	197	42	4	74a2c6cb8fcfe53dd9a2b36492a16c58f38e51c9
ToppCell	wk_20-22-Hematologic-Myeloid-S100A12-hi_cla._mono.\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	HCAR3 FCGR2C LILRA1 DMXL2	3.50e-05	197	42	4	e862561f61a1ae1ec858b34f8d9c9a7dc8894104
ToppCell	medial-Hematologic-Interstitial_Macrophage\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	LILRA1 DMXL2 FCGR2A FCGR2B	3.50e-05	197	42	4	13aec816e21754eac590a12c3a9c795c41108277
ToppCell	PBMC-Severe-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	HCAR3 DMXL2 FCGR2A RIN2	3.50e-05	197	42	4	3cc4e56a77f96a43f9b5a24cf1b9524c927ef795
ToppCell	3'-Pediatric_IBD-SmallIntestine-Hematopoietic-Myeloid-Monocytes\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	HCAR3 FCGR2C LILRA1 DMXL2	3.50e-05	197	42	4	d9d58c2fe40d9b5b9031fb7a71525a535927effe
ToppCell	saliva-Mild-Moderate_progression_d12-25-Myeloid-Macrophage-macrophage,_alveolar\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	LILRA1 DMXL2 RIN2 NUS1	3.50e-05	197	42	4	b17ac6c88dc53e54e04e8a79409d9a0de0be88dc
ToppCell	medial-2-Hematologic-Interstitial_Macrophage\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	LILRA1 DMXL2 FCGR2A FCGR2B	3.50e-05	197	42	4	38a74eeb2a4c8d6a86b133f02f4e6c641f16a3ac
ToppCell	10x5'-lymph-node_spleen-Myeloid_Monocytic\|lymph-node_spleen / Manually curated celltypes from each tissue	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	2541f1095ed91e6789cb888cf39a208b8107726a
ToppCell	Mild-Myeloid-Macrophages-FCN1_high\|Mild / Condition, Lineage, Cell class and cell subclass	LILRA1 FCGR2A FCGR2B RIN2	3.57e-05	198	42	4	17aab4dc3b2cd6eb7dda77dd51bdc20490fcfe19
ToppCell	Monocytes\|World / Immune cells in Kidney/Urine in Lupus Nephritis	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	8beccf03c9ec9cd02a96107a9d7ca9a6764c6a61
ToppCell	VE-mono1-\|VE / Condition, Cell_class and T cell subcluster	DMXL2 FCGR2A FCGR2B RIN2	3.57e-05	198	42	4	2959d6e4992c36040ec9637f5a2daed02b35cf30
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Macrophage-macrophage,_alveolar-Macro_c2-CCL3L1\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	7b61f427ed5ca8ad563e5f112fba950a24c9d956
ToppCell	VE-mono1\|VE / Condition, Cell_class and T cell subcluster	DMXL2 FCGR2A FCGR2B RIN2	3.57e-05	198	42	4	c742871b8ec4720b1848991551c7c1f4000ebd85
ToppCell	(4)_Monocyte\|World / shred on Cell_type and subtype	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	56f9ebf902fe81c590696ba4c88028deaf346841
ToppCell	medial-2-Hematologic-OLR1+_Classical_Monocyte\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	d0a63cb48deecfdb8902c9229e457b7678aff178
ToppCell	3'_v3-lymph-node_spleen-Myeloid_Monocytic-Classical_monocytes\|lymph-node_spleen / Manually curated celltypes from each tissue	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	187a04d498f0b355cb11c81172721698818082d6
ToppCell	distal-2-Hematologic-OLR1+_Classical_Monocyte\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	43179d92e45b14f6f3d63949a9d88c2c7531f7d1
ToppCell	10x5'-lymph-node_spleen-Myeloid_Monocytic-Classical_monocytes\|lymph-node_spleen / Manually curated celltypes from each tissue	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	934dacb67d71faa2f8732c39d7f8e64b0ee75396
ToppCell	medial-Hematologic-OLR1+_Classical_Monocyte-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	74f79fd3b173c236e79b8b8f59a3b7c02ea082c6
ToppCell	Immune-monocyte\|World / Lineage, Cell type, age group and donor	LILRA1 DMXL2 FCGR2A FCGR2B	3.57e-05	198	42	4	d3622da252fd580f1dc5c7478a8e23df5ec083cf
ToppCell	medial-Hematologic-OLR1+_Classical_Monocyte\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	3f21354eb3e5f0949aec21dc2a8940e70464ecc7
ToppCell	3'_v3-lymph-node_spleen-Myeloid_Monocytic\|lymph-node_spleen / Manually curated celltypes from each tissue	LILRA1 DMXL2 FCGR2A RIN2	3.57e-05	198	42	4	065c8a9655d19f93dfdb453c78bbfe7d857caf3e
ToppCell	wk_20-22-Hematologic-Myeloid-Non-cla._mono.\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	HCAR3 FCGR2C LILRA1 DMXL2	3.64e-05	199	42	4	969f66a9adb337fa9857fb00bcace2d30c35a6a5
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR3 LILRA1 FCGR2A RIN2	3.64e-05	199	42	4	3e09b3c2e2c57e5248981293020d2434e898e3e1
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	HCAR3 LILRA1 FCGR2A RIN2	3.64e-05	199	42	4	ae6b4b4557c6a9223acdee2a79bc780c5916d38a
ToppCell	distal-Hematologic-Myeloid_Dendritic_Type_1-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	PRMT9 FCGR2C LILRA1 FCGR2B	3.64e-05	199	42	4	78e70852acda95d2c770cdd539a46b291f929a78
ToppCell	3'_v3-GI_small-bowel-Myeloid_Mac-Intestinal_macrophages\|GI_small-bowel / Manually curated celltypes from each tissue	DMXL2 TMEM26 FCGR2A RIN2	3.64e-05	199	42	4	96070b5ffcbab4952970f43b536969ddd2ca5d14
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte-\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR3 LILRA1 FCGR2A RIN2	3.64e-05	199	42	4	99eec995aa20ac22a8dd045382bd15a15db0b87a
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte\|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09)	HCAR3 LILRA1 FCGR2A RIN2	3.64e-05	199	42	4	4eed28ef8c74d7131eeeabdd732a682d91e034dd
ToppCell	Parenchymal-NucSeq-Immune_Myeloid-Monocytic-Monocyte_CD16\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	LILRA1 DMXL2 FCGR2A FCGR2B	3.64e-05	199	42	4	ac866ae110967c5867ff4601939b79861d43df54
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	HCAR3 LILRA1 FCGR2A RIN2	3.64e-05	199	42	4	f234533254fd82b1ef2041e8405fe201d874018b
ToppCell	COVID-19_Convalescent-Myeloid-Non-classical_Monocyte\|COVID-19_Convalescent / Disease group, lineage and cell class	HCAR3 LILRA1 FCGR2A RIN2	3.64e-05	199	42	4	5253948a1d7fc3da571860e14cdde4e18222e13b
ToppCell	PBMC-Convalescent-Myeloid-Non-classical_Monocyte-Non-classical_Monocyte\|Convalescent / Location, Disease Group, Cell group, Cell class (2021.03.09)	HCAR3 LILRA1 FCGR2A RIN2	3.64e-05	199	42	4	aca9f75c690c6ed952bcbdc7e1e7eef7719f54ca
ToppCell	3'-Pediatric_IBD-SmallIntestine-Hematopoietic-Myeloid\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	HCAR3 FCGR2C LILRA1 DMXL2	3.64e-05	199	42	4	41d240d44bd6cc301a7879cacee104c874b4ba2c
ToppCell	Caecum-(6)_Macrophage-(60)_Macrophage\|Caecum / shred on region, Cell_type, and subtype	LILRA1 DMXL2 FCGR2A RIN2	3.72e-05	200	42	4	67b6cdeb07ffc5c9af7a3e738dd31256cf391e98
ToppCell	Transverse-Macrophage-Macrophage\|Transverse / Region, Cell class and subclass	LILRA1 DMXL2 FCGR2A RIN2	3.72e-05	200	42	4	17548806ba38008050244151d1216c69ef8a8310
ToppCell	Bronchial-NucSeq-Immune_Myeloid-Macrophage_other\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	DMXL2 CDCP1 FCGR2A FCGR2B	3.72e-05	200	42	4	78d75d381cb2b9a4c9eb7c32a07b014eaee39195
ToppCell	Bronchial-NucSeq-Immune_Myeloid-Monocytic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	LILRA1 DMXL2 FCGR2A FCGR2B	3.72e-05	200	42	4	8872d5fa101d413fb43b4231d476878678543035
ToppCell	Transverse-(6)_Macrophage\|Transverse / shred on region, Cell_type, and subtype	LILRA1 DMXL2 FCGR2A RIN2	3.72e-05	200	42	4	b28350de555fa756d2631f004f71d5ac69b1affe
ToppCell	Parenchymal-NucSeq-Immune_Myeloid-Monocytic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	LILRA1 DMXL2 FCGR2A FCGR2B	3.72e-05	200	42	4	fd72fe6565e2f4885481991492d58c323ab1ad40
ToppCell	Caecum-(6)_Macrophage\|Caecum / shred on region, Cell_type, and subtype	LILRA1 DMXL2 FCGR2A RIN2	3.72e-05	200	42	4	2ce3930645c3daf6be578f7881e57a58df61e75c
ToppCell	Caecum-Macrophage\|Caecum / Region, Cell class and subclass	LILRA1 DMXL2 FCGR2A RIN2	3.72e-05	200	42	4	d83209559187a4419df2508ecc5eb9f7d72fced3
Drug	MDL 20,610	FCGR2C FCGR2A FCGR2B	5.82e-08	5	42	3	CID000128209
Drug	TAN-1030A	FCGR2C FCGR2A FCGR2B	1.16e-07	6	42	3	CID009576886
Drug	TAN-999	FCGR2C FCGR2A FCGR2B	2.03e-07	7	42	3	CID000130283
Drug	AC1MHTIN	FCGR2C FCGR2A FCGR2B	2.03e-07	7	42	3	CID003011133
Drug	Intravenous Immunoglobulin	FCGR2C FCGR2A FCGR2B	3.25e-07	8	42	3	DB00028
Drug	AC1NSK5W	FCGR2C FCGR2A FCGR2B	4.87e-07	9	42	3	CID005311182
Drug	Palivizumab	FCGR2C FCGR2A FCGR2B	6.94e-07	10	42	3	DB00110
Drug	Denny-Jaffe reagent	FCGR2C FCGR2A FCGR2B	6.94e-07	10	42	3	CID003035979
Drug	Bevacizumab	FCGR2C FCGR2A FCGR2B	9.53e-07	11	42	3	DB00112
Drug	Tositumomab	FCGR2C FCGR2A FCGR2B	9.53e-07	11	42	3	DB00081
Drug	Alemtuzumab	FCGR2C FCGR2A FCGR2B	9.53e-07	11	42	3	DB00087
Drug	Efalizumab	FCGR2C FCGR2A FCGR2B	9.53e-07	11	42	3	DB00095
Drug	Alefacept	FCGR2C FCGR2A FCGR2B	9.53e-07	11	42	3	DB00092
Drug	Daclizumab	FCGR2C FCGR2A FCGR2B	1.27e-06	12	42	3	DB00111
Drug	Natalizumab	FCGR2C FCGR2A FCGR2B	1.27e-06	12	42	3	DB00108
Drug	Rituximab	FCGR2C FCGR2A FCGR2B	1.27e-06	12	42	3	DB00073
Drug	Ibritumomab	FCGR2C FCGR2A FCGR2B	1.27e-06	12	42	3	DB00078
Drug	Adalimumab	FCGR2C FCGR2A FCGR2B	1.27e-06	12	42	3	DB00051
Drug	Gemtuzumab ozogamicin	FCGR2C FCGR2A FCGR2B	1.27e-06	12	42	3	DB00056
Drug	Cetuximab	FCGR2C FCGR2A FCGR2B	1.27e-06	12	42	3	DB00002
Drug	Trastuzumab	FCGR2C FCGR2A FCGR2B	1.65e-06	13	42	3	DB00072
Drug	Basiliximab	FCGR2C FCGR2A FCGR2B	1.65e-06	13	42	3	DB00074
Drug	Abciximab	FCGR2C FCGR2A FCGR2B	2.09e-06	14	42	3	DB00054
Drug	Etanercept	FCGR2C FCGR2A FCGR2B	2.09e-06	14	42	3	DB00005
Drug	Muromonab	FCGR2C FCGR2A FCGR2B	2.62e-06	15	42	3	DB00075
Drug	AC1L9LSE	FCGR2C FCGR2A FCGR2B	3.21e-06	16	42	3	CID000448272
Drug	2cgx	FCGR2C FCGR2A FCGR2B	4.67e-06	18	42	3	CID001548380
Drug	R13-1	FCGR2C FCGR2A FCGR2B	5.54e-06	19	42	3	CID000009666
Drug	Loestrin	FCGR2C FCGR2A FCGR2B	7.59e-06	21	42	3	CID000062925
Drug	AC1Q5JRE	FCGR2C FCGR2A FCGR2B	8.77e-06	22	42	3	CID000188349
Drug	gamma-aminobutyric acid	TNPO1 HCAR3 FCGR2C NLGN2 GRIN3B FCGR2A FCGR2B	2.33e-05	474	42	7	CID000000119
Drug	LY 294002; Down 200; 10uM; PC3; HT_HG-U133A	CEACAM6 URB2 CABIN1 LETM1 SENP3	2.74e-05	193	42	5	4460_DN
Drug	Avermectin B1 [71751-41-2]; Down 200; 4.8uM; PC3; HT_HG-U133A	CEACAM6 VPS13D URB2 LETM1 SYNE2	3.10e-05	198	42	5	5864_DN
Drug	2-Br	FCGR2C FCGR2A FCGR2B	5.09e-05	39	42	3	CID000007244
Drug	AC1NS1CY	FCGR2C FCGR2A FCGR2B	5.50e-05	40	42	3	CID005326941
Drug	S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (2R)-2-[4-(2-methylpropyl)phenyl]propanethioate	FCGR2C FCGR2A FCGR2B	5.93e-05	41	42	3	CID009854504
Drug	AC1L1C1F	FCGR2C FCGR2A FCGR2B	1.01e-04	49	42	3	CID000001699
Drug	sodiosodium	FCGR2C FCGR2A FCGR2B	1.36e-04	54	42	3	CID000141233
Drug	NA-1	FCGR2C FCGR2A FCGR2B	2.05e-04	62	42	3	CID000446091
Drug	3,5-diaminocyclohexan-1-ol	FCGR2C FCGR2A FCGR2B	2.58e-04	67	42	3	CID004632239
Drug	cortisone 21-acetate	FCGR2C FCGR2A FCGR2B	2.93e-04	70	42	3	CID000002863
Drug	austin	FCGR2C FCGR2A FCGR2B	2.93e-04	70	42	3	CID000430632
Drug	H-Na	FCGR2C FCGR2A FCGR2B	3.45e-04	74	42	3	CID004369271
Drug	AC1L9IGO	CMKLR2 FCGR2C FCGR2A FCGR2B	3.64e-04	184	42	4	CID000445722
Drug	procainamide	HCAR3 FCGR2C FCGR2A FCGR2B	4.10e-04	190	42	4	CID000004913
Drug	iodide	MTNR1B CEACAM6 HCAR3 FCGR2C FCGR2A FCGR2B	4.14e-04	534	42	6	CID000024841
Drug	Rapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A	GDPD5 URB2 CABIN1 LETM1	4.35e-04	193	42	4	1667_DN
Drug	Piroxicam [36322-90-4]; Down 200; 12uM; HL60; HG-U133A	VPS13D CABIN1 HTT SENP3	4.44e-04	194	42	4	1405_DN
Drug	Hydroxytacrine maleate (R,S) [118909-22-1]; Down 200; 12.2uM; HL60; HT_HG-U133A	GDPD5 VPS13D CDCP1 HECTD3	4.44e-04	194	42	4	2430_DN
Drug	Tiletamine hydrochloride; Down 200; 15.4uM; MCF7; HT_HG-U133A	GDPD5 VPS13D CABIN1 SENP5	4.44e-04	194	42	4	6516_DN
Drug	tetrachloroethylene	FCGR2C FCGR2A FCGR2B	4.51e-04	81	42	3	CID000031373
Drug	Asiaticoside [16830-15-2]; Down 200; 4.2uM; MCF7; HT_HG-U133A	CEACAM6 VPS13D LETM1 HTT	4.53e-04	195	42	4	7004_DN
Drug	Acyclovir [59277-89-3]; Down 200; 17.8uM; HL60; HG-U133A	GDPD5 VPS13D MAN2B2 HTT	4.62e-04	196	42	4	2044_DN
Drug	radicicol; Down 200; 0.1uM; MCF7; HT_HG-U133A	VPS13D URB2 CDCP1 ATP10D	4.62e-04	196	42	4	5947_DN
Drug	Esculin Hydrate [531-75-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A	CEACAM6 GDPD5 CABIN1 RIN2	4.62e-04	196	42	4	5411_DN
Drug	Imipramine hydrochloride [113-52-0]; Down 200; 12.6uM; PC3; HT_HG-U133A	CMKLR2 VPS13D CABIN1 LETM1	4.62e-04	196	42	4	1807_DN
Drug	Dimethadione [695-53-4]; Down 200; 31uM; HL60; HT_HG-U133A	DMXL2 VPS13D HTT SENP5	4.62e-04	196	42	4	3029_DN
Drug	Convolamine hydrochloride [500-56-1]; Up 200; 11.8uM; HL60; HG-U133A	VPS13D NUS1 SENP3 SENP5	4.70e-04	197	42	4	1779_UP
Drug	alpha-estradiol; Down 200; 0.01uM; HL60; HT_HG-U133A	GDPD5 VPS13D CABIN1 SENP5	4.70e-04	197	42	4	6169_DN
Drug	Nicardipine hydrochloride [54527-84-3]; Down 200; 7.8uM; HL60; HG-U133A	VPS13D HTT SENP3 SENP5	4.70e-04	197	42	4	1600_DN
Drug	Cyproterone acetate [427-51-0]; Up 200; 9.6uM; MCF7; HT_HG-U133A	VPS13D ARHGEF28 CDCP1 ATP10D	4.80e-04	198	42	4	6806_UP
Drug	Trifluoperazine dihydrochloride [440-17-5]; Down 200; 8.4uM; PC3; HT_HG-U133A	DMXL2 VPS13D CABIN1 SENP3	4.80e-04	198	42	4	6341_DN
Drug	Fursultiamine Hydrochloride [2105-43-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	CEACAM6 GDPD5 VPS13D SENP5	4.80e-04	198	42	4	7349_DN
Drug	(S)-propranolol hydrochloride [4199-10-4]; Down 200; 13.6uM; HL60; HT_HG-U133A	CABIN1 LETM1 HTT SENP5	4.80e-04	198	42	4	2961_DN
Drug	Sulfinpyrazone [57-96-5]; Up 200; 9.8uM; HL60; HG-U133A	CEACAM6 HECTD3 HTT SENP5	4.80e-04	198	42	4	1574_UP
Drug	Nimodipine [66085-59-4]; Down 200; 9.6uM; MCF7; HT_HG-U133A	CEACAM6 VPS13D ARHGEF28 CABIN1	4.89e-04	199	42	4	6480_DN
Drug	2-Chloropyrazine [14508-49-7]; Up 200; 35uM; MCF7; HT_HG-U133A	EFR3B GDPD5 DMXL2 ARHGEF28	4.89e-04	199	42	4	3570_UP
Drug	Articaine hydrochloride [23964-57-0]; Down 200; 12.4uM; HL60; HT_HG-U133A	CDCP1 CABIN1 HTT SENP5	4.89e-04	199	42	4	3138_DN
Drug	Lysergol [602-85-7]; Up 200; 15.8uM; HL60; HT_HG-U133A	GDPD5 VPS13D CDCP1 LETM1	4.89e-04	199	42	4	1325_UP
Drug	Trolox [53188-07-1]; Up 200; 16uM; HL60; HG-U133A	GDPD5 CDCP1 LETM1 SENP3	4.89e-04	199	42	4	1734_UP
Drug	Methapyrilene hydrochloride [135-23-9]; Up 200; 13.4uM; MCF7; HT_HG-U133A	EFR3B VPS13D CABIN1 ATP10D	4.89e-04	199	42	4	3205_UP
Drug	phosphorylcholine	CMKLR2 FCGR2C FCGR2A FCGR2B	5.07e-04	201	42	4	CID000001014
Disease	malaria (implicated_via_orthology)	FCGR2C FCGR2A FCGR2B	2.08e-07	9	41	3	DOID:12365 (implicated_via_orthology)
Disease	low affinity immunoglobulin gamma Fc region receptor II-a measurement	FCGR2C FCGR2A FCGR2B	1.67e-06	17	41	3	EFO_0021969
Disease	low affinity immunoglobulin gamma Fc region receptor II-b measurement	FCGR2C FCGR2A FCGR2B	5.61e-06	25	41	3	EFO_0021970
Disease	glycosyl ceramide (d16:1/24:1, d18:1/22:1) measurement	ATP10D SYNE2	5.65e-06	3	41	2	EFO_0800530
Disease	SYSTEMIC LUPUS ERYTHEMATOSUS	FCGR2A FCGR2B	2.82e-05	6	41	2	152700
Disease	systemic lupus erythematosus (implicated_via_orthology)	FCGR2C FCGR2A FCGR2B	2.96e-05	43	41	3	DOID:9074 (implicated_via_orthology)
Disease	lymphoid leukemia (is_implicated_in)	FCGR2A FCGR2B	3.94e-05	7	41	2	DOID:1037 (is_implicated_in)
Disease	glycosyl ceramide (d18:1/20:0, d16:1/22:0) measurement	ATP10D SYNE2	3.94e-05	7	41	2	EFO_0800551
Disease	low affinity immunoglobulin gamma Fc region receptor II-a/b measurement	FCGR2A FCGR2B	3.94e-05	7	41	2	EFO_0008211
Disease	plexin-B2 measurement	FCGR2C FCGR2B	6.74e-05	9	41	2	EFO_0021867
Disease	Systemic lupus erythematosus	FCGR2A FCGR2B	1.03e-04	11	41	2	cv:C0024141
Disease	autoimmune thrombocytopenic purpura (is_implicated_in)	FCGR2A FCGR2B	1.96e-04	15	41	2	DOID:8924 (is_implicated_in)
Disease	–	FCGR2A FCGR2B	2.23e-04	16	41	2	611162
Disease	Malaria, susceptibility to	FCGR2A FCGR2B	2.23e-04	16	41	2	cv:C1970028
Disease	waist-hip ratio	EFR3B CMKLR2 HCAR3 DMXL2 MMS22L TBC1D23 SYNE2 HTT	2.44e-04	1226	41	8	EFO_0004343
Disease	Malaria	FCGR2A FCGR2B	3.52e-04	20	41	2	C0024530
Disease	malaria (is_implicated_in)	FCGR2A FCGR2B	5.10e-04	24	41	2	DOID:12365 (is_implicated_in)
Disease	sphingolipid measurement	ATP10D SYNE2	1.42e-03	40	41	2	EFO_0004622
Disease	birth weight, parental genotype effect measurement	MTNR1B FCGR2C FCGR2B	2.41e-03	192	41	3	EFO_0004344, EFO_0005939
Disease	low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio	HCAR3 SYNE2 HTT	2.71e-03	200	41	3	EFO_0004611, EFO_0020945

Protein segments in the cluster

Peptide	Gene	Start	Entry
PVAHWHLIVSNLTIL	URB2	736	Q14146
IVESLIHAWEHLLLQ	PRMT9	266	Q6P2P2
VALHPLVILNISDHW	COPS6	41	Q7L5N1
ILHLPVELHDFSWKL	CDCP1	436	Q9H5V8
HLTVLSEWLVLQTPH	FCGR2A	116	P12318
LTVLSEWLVLQTPHL	FCGR2B	126	P31994
LTIFHALVVLSWPHV	CCNI2	256	Q6ZMN8
PLDLIHLWLHESARV	DNAH11	2731	Q96DT5
AWTKDDVILHVLPLH	ACSF3	231	Q4G176
LIPNIKHLVHLDWVS	DMXL2	1161	Q8TDJ6
LLHLVIESKSLTWIH	ATP10D	1241	Q9P241
LVLALTHLELPLEWT	ARHGEF28	136	Q8N1W1
HLIHILMWTTNLEPL	PRAMEF17	326	Q5VTA0
HHVSNIPLKLWERII	LLGL2	391	Q6P1M3
LHLHLDIHWLVLEIL	MMS22L	211	Q6ZRQ5
LHVPWKEVLLTASLL	CEACAM6	11	P40199
WLDLHLHQEIPTSLL	LETM1	401	O95202
HTPLHICLIWLLTVV	MTNR1B	156	P49286
LTVLSEWLVLQTPHL	FCGR2C	126	P31995
AIKPVLIHLDNHSLW	EFR3B	251	Q9Y2G0
WHIRLTEIVSLPSHL	NUS1	256	Q96E22
HWLHKIGLVVILAST	GDPD5	121	Q8WTR4
TLEALSWHLIHEQIP	HTT	2256	P42858
SWHLIHEQIPLSLDL	HTT	2261	P42858
HVSSVLPWIILHRII	CABIN1	841	Q9Y6J0
LNDTSVVHPVLWLLL	MAN2B2	811	Q9Y2E5
WLELVPHLHNLHTEL	NLGN2	601	Q8NFZ4
HLQLHWASPLETLLD	GRIN3B	146	O60391
IVPSLWLLELHHETQ	TMEM26	76	Q6ZUK4
GLIWTIILHFHIEKL	SYNE2	126	Q8WXH0
VERHVLPILWHFLNT	TOGARAM2	921	Q6ZUX3
HVWSLPSDLLELLVL	LILRA1	206	O75019
PSVVVRIHIFWLLHT	HCAR3	246	P49019
PDLTLIRHHVLTWVK	CMKLR2	196	P46091
LLIPIHLEVHWSLIS	SENP3	456	Q9H4L4
ILDRLLHTHPIWLQL	RIN2	86	Q8WYP3
LHTHPIWLQLSLSEE	RIN2	91	Q8WYP3
LLLIPIHLEVHWSLI	SENP5	636	Q96HI0
LLAHRPWLITKEHIQ	SESN3	161	P58005
LSWIHLLKPLVHLQL	TBC1D23	126	Q9NUY8
ILPLLKELLFHHEWV	TNPO1	406	Q92973
TLSLWTLPDVLIIHL	USP31	631	Q70CQ4
WLLLVHDFLHTPSDI	VPS13D	2406	Q5THJ4
KILDSVLHHLVPAWD	HECTD3	416	Q5T447